Pfizer Inc and BioNTech SE received U.S. regulatory authorization for their COVID-19 vaccine on Friday, making it the first inoculation against the new coronavirus to get a regulatory green light in the United States.
The following is what we know about the race to deliver vaccines to help end the coronavirus pandemic that has killed 1.59 million people worldwide:
WHO IS FURTHEST ALONG?
U.S. drugmaker Pfizer and German partner BioNTech are the coronavirus vaccine trailblazers.
On Nov. 18, they became the first in the world to release full late-stage trial data. Britain was the first to approve the shot for emergency use on Dec. 3, followed by Canada on Dec. 9 and the U.S. Food and Drug Administration (FDA) on Dec. 11.
The European Medicines Agency (EMA) is due to complete its review of the shot by Dec. 29 and India is accelerating its review.
WHO WILL BE NEXT?
U.S. pharmaceutical company Moderna is ahead of the pack at this point. It was next to release full data analysis for a late-stage trial on Nov. 30, with its vaccine showing a 94.1% efficacy rate. FDA advisers are due to review it on Dec. 17 and the EMA will do so by Jan. 12.
WHO ELSE IS IN THE RUNNING?
Britain's AstraZeneca is seeking approval for its vaccine in Britain after announcing interim late-stage trial data on Nov. 23. It had an average efficacy rate of 70% and as much as 90% for a subgroup of trial participants who got a half dose first, followed by a full dose.
However, it is not clear how the regulator will deal with the different dosages in the efficacy data in its assessment. While India is conducting an accelerated review, it has asked for more data. AstraZeneca is also in discussions with the EMA, which is conducting a rolling review of the vaccine.
U.S. drugmaker Johnson & Johnson plans to deliver trial data this year, or early in 2021, teeing it up for U.S. authorization in February if its shot is effective. It reduced the enrollment target for its clinical trial to 40,000 volunteers from 60,000 on Dec. 9, potentially speeding results which are tied to how quickly participants become infected.
U.S. firm Novavax is running a late-stage trial in Britain with data due in the first quarter of 2021. It expects to start a large-scale trial in the United States this month.
France's Sanofi and Britain's GlaxoSmithKline, however, announced a setback on Dec. 11 in their attempts to develop a vaccine. The drugmakers said it showed an insufficient immune response in older people in mid-stage trials and that they would start a new study in February.
WHAT HAPPENS IN THE TRIALS?
The companies typically test their vaccines against a placebo - typically saline solution - in healthy volunteers to see if the rate of COVID-19 infection among those who got the vaccine is significantly lower than in those who received the dummy shot.
HOW ARE VOLUNTEERS INFECTED?
The trials rely on subjects becoming naturally infected with COVID-19, so how long it takes to generate results largely depends on how pervasive the virus is where trials are being conducted. Each drugmaker has targeted a specific number of infections to trigger a first analysis of their data.
HOW WELL ARE THE VACCINES SUPPOSED TO WORK?
The World Health Organization ideally wants to see at least 70% efficacy. The FDA wants at least 50% - which means there must be at least twice as many infections among volunteers who received a placebo as among those in the vaccine group. The EMA has said it may accept a lower efficacy level.
WHAT ABOUT RUSSIA AND CHINA?
While Pfizer's shot was the first to be rolled out following the publication of full Phase III trial data, Russia and China have been inoculating their citizens for months with several different vaccines still undergoing late-stage trials.
Russia said on Nov. 24 that its Sputnik V vaccine, developed by the Gamaleya Institute, was 91.4% effective based on interim late-stage trial results. It started vaccinations in August and has inoculated more than 100,000 people so far.
AstraZeneca said on Dec. 11 that it would test a combination of its vaccine with one of Sputnik V's two components to try to boost the efficacy of the shot it is developing with Oxford University.
China launched an emergency use programme in July aimed at essential workers and others at high risk of infection. It has vaccinated about one million people as of mid-November using at least three shots - two developed by the state-backed China National Biotec Group (CNBG) and one by Sinovac Biotech.
Sinovac said on Nov. 18 that mid-stage trial results showed its CoronaVac shot triggered a quick immune response and interim data from its late stage trial could come this year.
The Butantan Institute, a Brazilian biomedical centre, is producing CoronaVac and aims to make 1 million doses a day ahead of a vaccine campaign to be launched late January.
The United Arab Emirates, meanwhile, said on Dec. 9 that one of the CNBG vaccines was 86% effective based on interim results from a late-stage trial in the Gulf Arab state.
Reuters
Sat Dec 12 2020
A nurse administers the Pfizer/BioNTech COVID-19 vaccine to a man at a vaccination centre, on the first day of the largest immunisation programme in the British history, in Cardiff, Wales, Britain Dec 8, 2020. REUTERSpic
Rebel: Tak adil kalau tak tengok, dengar komen orang dari luar saja - Awie
Awie memberitahu kisah perjuangan berkaitan kumpulan pertubuhan yang cuba diketengahkan itu sudah lama ada di dalam masyarakat, cuma tidak diketahui saja pergerakannya.
Nahas helikopter: Kementerian pertahanan, ATM aktifkan Tabung Tragedi Lumut 24
Kementerian Pertahanan dan Angkatan Tentera Malaysia menubuhkan tabung khas 'Tabung Tragedi Lumut 24' bagi orang ramai menghulurkan bantuan kewangan.
Blok Negara Islam Sedang ‘Stress’? Langsung Dialog 4 Menteri Luar – Arab Saudi, Turkiye, Jordan dan Mesir
Situasi meruncing di Gaza, konflik Iran-Israel dan ditambah pula persaingan kuat dua kuasa, Amerika Syarikat dan China dilihat terus membayangi percaturan geopolitik dan geoekonomi negara-negara Islam di Asia Barat. Menteri Luar Turkiye dan Arab Saudi antara yang tampil duduk sepentas
membincangkan apa lagi yang bakal jadi nanti.
#SpecialMeeting24
membincangkan apa lagi yang bakal jadi nanti.
#SpecialMeeting24
Tiada bukti kaitkan guru dengan kes pedofilia di MRSM Tumpat - Polis
Tiada bukti dapat dikaitkan dengan seorang guru berhubung dakwaan berlaku kes pedofilia di Maktab Rendah Sains Mara (MRSM) Tumpat.
Polis tahan pasangan kekasih, rampas pistol dan dadah bernilai RM4.73 juta
Polis menahan sepasang kekasih dipercayai terlibat kegiatan pengedaran dadah di sekitar Lembah Klang dan merampas pelbagai jenis dadah bernilai RM4.73 juta dalam serbuan di sebuah kondominium di Pucho
Suami kongsi gambar nikah, netizen beri kata-kata semangat buat Irma Hasmie
Perkongsian Redza menimbulkan respons yang pelbagai dalam kalangan netizen. Beberapa peminat turut dilihat memberikan kata-kata semangat kepada Irma.
Kotak hitam helikopter mendarat cemas di Pulau Angsa dihantar ke Itali
Kotak hitam helikopter AW139 milik Maritim Malaysia yang melakukan pendaratan cemas di sekitar perairan Pulau Angsa, Kuala Selangor telah dihantar ke Itali.
Leftenan Muda Min Youn satu-satunya penuntut bangsa Cina tamat latihan Komando
Leftenan Muda Chan Ming Youn dari Batalion Kedua Rejimen Renjer Diraja menjadi satu-satunya penuntut berbangsa cina yang berjaya menamatkan Kursus Asas Komando Gerup Gerak Khas (GGK) baru-baru ini.
Kawalan sempadan dipertingkat di sempadan Malaysia-Thailand
Polis Kelantan memantau perkembangan kejadian letupan dan insiden tembak menembak di Sungai Golok awal pagi Isnin dengan meningkatkan kawalan keselamatan di sempadan negara.
Pelancongan China dijangka meningkat
Sektor pelancongan China dijangka menyaksikan lonjakan berikutan perkembangan pasaran yang dibawa oleh Festival Qingming awal bulan ini.
Suruhanjaya Eropah luluskan vaksin COVID-19 versi terkini
Suruhanjaya Eropah sudah meluluskan versi terkini vaksin COVID-19 yang dibangunkan oleh BioNTech-Pfizer.
Kempen MyPELINDUNG didik masyarakat terus perangi COVID-19
Meskipun Malaysia telah mencapai kemajuan ketara, namun virus COVID-19 tetap kekal sebagai satu kebimbangan kesihatan.
Puting beliung musnahkan gudang utama Pfizer
Syarikat farmaseutikal Pfizer mengesahkan bahawa kompleks tersebut telah rosak akibat puting beliung yang berlaku dekat Rocky Mount.
Belgium akan musnahkan hampir 6 juta vaksin COVID-19 yang luput
Belgium tidak boleh menggunakan lagi lebihan vaksin asli dan 2.6 juta dos Moderna dan 3.3 juta dos Pfizer akan dimusnahkan secepat mungkin.
WEF2023: Pfizer umum penjualan tanpa untung kepada negara miskin
Ini termasuk ubat luar paten, menjadikan jumlah keseluruhan produk yang ditawarkan kepada lebih 500 jenis.
Vaksin COVID-19: AS setuju cadangan dos penggalak kepada 12 tahun ke atas
CDC dijangka menerima pakai cadangan itu, sebagai langkah sebelum suntikan boleh dimulakan.
Moderna saman Pfizer, BioNTech kerana tiru paten
Moderna mendakwa, kedua-dua syarikat itu meniru teknologi yang dihasilkannya sejak sekian lama sebelum pandemik bermula.
COVID-19: Singapura beri suntikan dos penggalak kepada kanak-kanak berusia 5 hingga 11 tahun pada suku keempat
Kementerian Kesihatan sudah menerima cadangan yang dikemukakan Jawatankuasa Pakar mengenai Vaksinasi COVID-19 (EC19V).
COVID-19: Vaksin Pfizer, Moderna lulus untuk kanak-kanak 6 bulan ke 5 tahun
Dengan kelulusan ini, sekitar 18 juta kanak-kanak dalam kumpulan umur berkenaan layak untuk menerima vaksin.
PICKids: Tiada lagi vaksin Pfizer, Sinovac untuk kanak-kanak selepas 31 Mei - ProtectHealth
Sebelum ini Kementerian Kesihatan Malaysia (KKM) memutuskan untuk melanjutkan tarikh akhir pemberian vaksin PICKids dari 15 Mei kepada 31 Mei.